[{"id":"8a12a2b1-4461-4e08-a123-bacd09514bb9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03618667","created_at":"2021-01-18T17:46:59.647Z","updated_at":"2024-07-02T16:35:48.108Z","phase":"Phase 2","brief_title":"GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification","source_id_and_acronym":"NCT03618667","lead_sponsor":"Samsung Medical Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GC-1118A"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 01/22/2018","start_date":" 01/22/2018","primary_txt":" Primary completion: 09/08/2018","primary_completion_date":" 09/08/2018","study_txt":" Completion: 04/28/2022","study_completion_date":" 04/28/2022","last_update_posted":"2023-05-12"},{"id":"e5913600-1859-40be-b59a-287e730ac963","acronym":"","url":"https://clinicaltrials.gov/study/NCT04077255","created_at":"2021-01-18T19:58:01.930Z","updated_at":"2024-07-02T16:35:59.842Z","phase":"Phase 2","brief_title":"EGFR-targeted Therapy for Gastric Cancer","source_id_and_acronym":"NCT04077255","lead_sponsor":"National Cancer Center, Korea","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • rogaratinib (BAY 1163877) • GC-1118A"],"overall_status":"Recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2022-11-30"},{"id":"efef7fc3-6ed0-4537-9751-b41c852c3812","acronym":"","url":"https://clinicaltrials.gov/study/NCT03454620","created_at":"2021-01-18T17:02:02.918Z","updated_at":"2024-07-02T16:36:16.137Z","phase":"Phase 1b/2a","brief_title":"A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy","source_id_and_acronym":"NCT03454620","lead_sponsor":"Green Cross Corporation","biomarkers":" EGFR • HER-2 • KRAS • BRAF • NRAS","pipe":" | ","alterations":" EGFR expression • KRAS wild-type • BRAF wild-type • NRAS wild-type • BRAF wild-type + NRAS wild-type","tags":["EGFR • HER-2 • KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • KRAS wild-type • BRAF wild-type • NRAS wild-type • BRAF wild-type + NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium • GC-1118A"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 04/02/2018","start_date":" 04/02/2018","primary_txt":" Primary completion: 09/17/2021","primary_completion_date":" 09/17/2021","study_txt":" Completion: 01/10/2022","study_completion_date":" 01/10/2022","last_update_posted":"2022-03-03"},{"id":"a8d83fb7-8852-4913-b244-46c50c3f6e46","acronym":"","url":"https://clinicaltrials.gov/study/NCT02352571","created_at":"2021-01-18T11:11:32.753Z","updated_at":"2024-07-02T16:37:30.832Z","phase":"Phase 1","brief_title":"Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer","source_id_and_acronym":"NCT02352571","lead_sponsor":"Green Cross Corporation","biomarkers":" HER-2 • KRAS","pipe":"","alterations":" ","tags":["HER-2 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GC-1118A"],"overall_status":"Unknown status","enrollment":" Enrollment 72","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 06/01/2017","study_completion_date":" 06/01/2017","last_update_posted":"2016-07-06"}]